Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05058976 · ClinicalTrials.gov registry record · Phase 4
Romosozumab Use to Build Skeletal Integrity
A Phase 4 study of Osteoporosis and Osteoporosis, Postmenopausal, sponsored by Susan L. Greenspan.
- Active
- Registry status
- Phase 4
- Development phase
- 184
- Enrollment target
- 1
- Study location
NCT05058976: Active Phase 4 study of Osteoporosis and Osteoporosis, Postmenopausal, sponsored by Susan L. Greenspan.
NCT05058976 is a Phase 4 study of Osteoporosis and Osteoporosis, Postmenopausal that is active but no longer recruiting, run by Susan L. Greenspan. The registered enrollment target is 184 participants, below the 1,544-participant average among 84 other Osteoporosis trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05058976, a Phase 4 study of Osteoporosis and Osteoporosis, Postmenopausal, is active but no longer recruiting, sponsored by Susan L. Greenspan.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 184 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out if one year of romosozumab (Evenity®), a monthly injection given in the arm under the skin, prior to an infusion of zoledronic acid Reclast®, works to treat bone loss and prevent it from worsening in older women (ages 65 and older) who have osteoporosis and reside in long-term care (LTC) facilities.
Primary Outcome
Bone Mineral Density (BMD) of the total hip at 24 months as assessed by dual-energy x-ray absorptiometry (DXA)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Romosozumab
- DRUG Zoledronic acid
- DIETARY_SUPPLEMENT Calcium and Vitamin D
Study Locations (1)
Pennsylvania
- UPMC Senior Communities - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2021-09-15 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 4 |
What the registry record for NCT05058976 still lists
NCT05058976 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 84 other Osteoporosis trials with a reported enrollment target (88% lower).
The record links to 3 conditions, with Osteoporosis appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT05058976 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05058976 about?
NCT05058976 is a clinical study titled "Romosozumab Use to Build Skeletal Integrity". The purpose of this study is to find out if one year of romosozumab (Evenity®), a monthly injection given in the arm under the skin, prior to an infusion of zoledronic acid Reclast®, works to treat bone loss and prevent it from worsening in older women (ages 65 and older) who have osteoporosis and r...
What is the current status of trial NCT05058976?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 184 participants. The study started on 2021-09-15. Estimated completion is 2027-03-31.
What conditions does trial NCT05058976 study?
This clinical trial studies the following conditions: Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Fracture.
What interventions are being tested in trial NCT05058976?
The interventions under investigation include: Placebo (DRUG), Romosozumab (DRUG), Zoledronic acid (DRUG), Calcium and Vitamin D (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05058976?
This trial is sponsored by Susan L. Greenspan, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05058976 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05058976's enrollment target sits among peer trials
184 32nd of 84 higher than 53 of 84 other Osteoporosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Preserving Geriatric Muscle With an Osteoporosis Medication
RECRUITING · Phase 4
-
Combined Anabolic Therapy
RECRUITING · Phase 4
-
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
ACTIVE NOT RECRUITING · Phase 4
-
Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study
ACTIVE NOT RECRUITING · Phase 4
-
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
ACTIVE NOT RECRUITING · Phase 4
-
Trial of Parkinson's And Zoledronic Acid
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI